
Curasight's Strategic Phase 1 Trial in Brain Cancer
Curasight advances its theranostic platform with a pivotal Phase 1 trial in collaboration with Premier Research.

Curasight advances its theranostic platform with a pivotal Phase 1 trial in collaboration with Premier Research.

Curasight har annonserat en nyemission som kan inbringa upp till DKK 100 miljoner.

Curasight presenterar nyemission och ger en uppdatering om affärsutvecklingen under Q1 2025.

Curasight har registrerat sitt informationsdokument för den kommande nyemissionen hos den danska finansinspektionen.

Curasight navigates a challenging 2024 with strategic partnerships and clinical advancements.

Curasight announces a successful rights issue to strengthen its financial base for upcoming clinical milestones.

Curasight announces a rights issue aiming to raise DKK 100 million, bolstering its innovative cancer treatment technologies.

Curasight's shareholders approve key resolutions to expand share capital authorization, setting the stage for strategic growth.

Curasight föreslår att utöka styrelsens befogenheter för att öka aktiekapitalet och utfärda teckningsoptioner.

Curasight announces a significant rights issue to support its innovative cancer diagnostics and treatment platforms.

Curasight har offentliggjort viktiga datum för 2025, inklusive deras Årsstämma och rapporteringsschema.

Curasight fortsätter att utveckla sina innovativa plattformar trots ekonomiska utmaningar.